Tag: PD-L1
Sun Pharma completes its acquisition of Checkpoint Therapeutics
As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma